![]() | ![]() |
Formats:
|
|||||||||||||||||||||||||||||||||||||||||
Copyright : © 2007 Menashe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Genetic Elucidation of Human Hyperosmia to Isovaleric Acid 1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel 2 Crown Human Genome Center, Weizmann Institute of Science, Rehovot, Israel 3 Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America 4 Department of Otolaryngology, Meir Hospital, Kfar Saba, Israel 5 National Blood Group Reference Laboratory, Magen David Adom National Blood Services Center, Ramat-Gan, Israel Trudy F. C Mackay, Academic Editor North Carolina State University, United States of America * To whom correspondence should be addressed. E-mail: doron.lancet/at/weizmann.ac.il Received April 16, 2007; Accepted August 31, 2007. This article has been cited by other articles in PMC.Abstract The genetic basis of odorant-specific variations in human olfactory thresholds, and in particular of enhanced odorant sensitivity (hyperosmia), remains largely unknown. Olfactory receptor (OR) segregating pseudogenes, displaying both functional and nonfunctional alleles in humans, are excellent candidates to underlie these differences in olfactory sensitivity. To explore this hypothesis, we examined the association between olfactory detection threshold phenotypes of four odorants and segregating pseudogene genotypes of 43 ORs genome-wide. A strong association signal was observed between the single nucleotide polymorphism variants in OR11H7P and sensitivity to the odorant isovaleric acid. This association was largely due to the low frequency of homozygous pseudogenized genotype in individuals with specific hyperosmia to this odorant, implying a possible functional role of OR11H7P in isovaleric acid detection. This predicted receptor–ligand functional relationship was further verified using the Xenopus oocyte expression system, whereby the intact allele of OR11H7P exhibited a response to isovaleric acid. Notably, we also uncovered another mechanism affecting general olfactory acuity that manifested as a significant inter-odorant threshold concordance, resulting in an overrepresentation of individuals who were hyperosmic to several odorants. An involvement of polymorphisms in other downstream transduction genes is one possible explanation for this observation. Thus, human hyperosmia to isovaleric acid is a complex trait, contributed to by both receptor and other mechanisms in the olfactory signaling pathway. Author Summary Humans can accurately discern thousands of odors, yet there is considerable inter-individual variation in the ability to detect different odors, with individuals exhibiting low sensitivity (hyposmia), high sensitivity (hyperosmia), or even “blindness” (anosmia) to particular odors. Such differences are thought to stem from genetic differences in olfactory receptor (OR) genes, which encode proteins that initiate olfactory signaling. OR segregating pseudogenes, which have both functional and inactive alleles in the population, are excellent candidates for producing this olfactory phenotype diversity. Here, we provide evidence that a particular segregating OR gene is related to sensitivity to a sweaty odorant, isovaleric acid. We show that hypersensitivity towards this odorant is seen predominantly in individuals who carry at least one copy of the intact allele. Furthermore, we demonstrate that this hyperosmia is a complex trait, being driven by additional factors affecting general olfactory acuity. Our results highlight a functional role of segregating pseudogenes in human olfactory variability, and constitute a step towards deciphering the genetic basis of human olfactory variability. Introduction Humans are highly variable in their olfactory perception. Such phenotypic diversity has been known for nearly a century, indicating a widespread occurrence of odorant-specific sensitivity variations [1–6] as well as of differences in general olfactory acuity [1–3]. These variations in chemosensory sensitivity often span several orders of magnitude [1,4–8], with extreme manifestation in specific anosmia or “smell blindness” [9–11]. Such human olfactory traits have been suggested to constitute a complex trait, affected by both environmental and genetic factors [6,8,11–13]. While specific anosmia and its milder representation, specific hyposmia, have been extensively studied, less attention has been devoted to the study of the other extreme of the olfactory threshold spectrum, hyperosmia [14,15]. Considerable evidence points to a significant genetic contribution to olfactory threshold variation. For example, a higher concordance of olfactory thresholds towards androstenone was found in monozygotic twins than in dizygotic twins [13,16]. Moreover, a family-based study with pentadecalactone and isovaleric acid (IVA) [11] suggested that for some odorants anosmia constitutes a recessive Mendelian trait. Corroborating evidence was reported in particular mouse strains [17], in which odor-specific threshold differences to IVA were shown to be recessively inherited [18,19]. A subsequent linkage analysis of this phenotype found association with two distinct genomic loci, on mouse Chromosomes 4 and 6 [18]. Nevertheless, the genes underlying this sensory trait remain unknown. In the nematode Caenorhabditis elegans, on the other hand, mutations in a defined odorant receptor gene (odr-10) were shown to be responsible for specific response deficits to the odorant diacetyl [20]. Olfactory receptors (ORs) mediate the first step in odorant recognition [21], and their polymorphisms likely constitute the molecular basis for odorant-specific threshold variations. Of the 856 OR genes and pseudogenes dispersed throughout the entire human genome [22,23], a subclass of more than 60 OR loci appear particularly relevant, as they harbor damaging single nucleotide polymorphisms (SNPs) in their coding regions, leading them to segregate between an intact and a disrupted (pseudogenized) allele in the human population [24,25]. Each of these segregating pseudogenes (SPGs) is a natural knockout with a potential to underlie sensitivity variations towards certain chemosensory ligands. As a group, SPG loci harbor a remarkable combinatorial genetic diversity [24], perhaps one of the largest in the human genome [26]. To explore the possible involvement of OR SPGs in human olfactory threshold variation, we launched a genotype–phenotype association study of the underlying SNPs of 43 OR segregating loci and olfactory threshold measurements for four odorants in 377 individuals. We found a statistically significant association between the presence of a nonsense SNP within the coding region of the OR OR11H7P and detection threshold differences for the sweaty odorant IVA, suggesting a locus related to specific hyperosmia. This predicted OR–ligand relationship was validated by an in vitro expression assay [27]. Furthermore, we observed a significant concordance between odorant thresholds within individuals, likely governed by another inherent mechanism affecting general olfactory sensitivity. Our results suggest that the extensive olfactory threshold variation among humans is a complex trait, contributed to both by OR-specific variations and by potential inter-individual differences in downstream components in the olfactory signaling pathway. Results Human Olfactory Threshold Variation To study the possible genetic mechanism of human olfactory threshold variation, we measured detection thresholds of four odorants—isoamyl acetate (IAA), isovaleric acid (IVA), L-carvone (LCA), and cineole (CIN)—in 377 individuals. In accordance with previous observations [10], a broad Gaussian distribution was seen for all odorants, spanning the entire concentration range (10−2–10−6 M; Figure 1
Genotype–Phenotype Association To test the possible involvement of OR SPGs in the observed odorant-specific olfactory threshold differences, we genotyped the underlying disrupting SNPs of 52 candidate OR SPGs (Table S2) in 377 individuals for whom genomic DNA was available. Of these, the genotypes of nine SNPs did not meet our quality assurance requirements (see Materials and Methods) and thus were removed from further scrutiny. The genotypes of the remaining 43 SNPs were further used for our genotype–phenotype analysis. Based on previous studies [11,13,18,19], we assumed Mendelian recessive inheritance of specific hyposmia, thus grouping together homozygous intact and heterozygous individuals. Comparison of the olfactory thresholds for individuals carrying different OR genotypes revealed a strong association signal between the genotyped SNP in OR11H7P and sensitivity to the odorant IVA (F =18.4, p = 2.29 × 10−5) (Figure 2
In Vitro Functional Expression Our genotype–phenotype analysis implies a functional relation between OR11H7P and the odorant IVA. To test this possibility, we coexpressed the intact allele of OR11H7P (OR11H7Pi) with human GNAL (guanine nucleotide binding protein [G protein], alpha activating activity polypeptide, olfactory type) and human CFTR (cystic fibrosis transmembrane conductance regulator [ATP-binding cassette sub-family C, member 7]) in Xenopus (frog) oocytes, and tested against various concentrations of IVA (from 30 μM to 10 mM; data not shown). OR11H7Pi responded to 3 mM IVA (Figure 4
Inter-Odorant Threshold Correlation A linear regression model reveals that the OR11H7P polymorphism explains ~8% (r2 = 0.08) of the IVA threshold variation in our data. Another ~50% of this variation is attributed to intra-individual variance in our olfactory threshold measurements (Figure S1). Thus, ~40% of the variation in human IVA sensitivity remains unexplained. We hypothesized that other mechanisms affecting the general olfactory sensitivity might contribute to the threshold variation towards IVA as well as to all other odorants. If true, this would be revealed as inter-odorant threshold concordances within individuals. Indeed, testing for such inter-odorant threshold correlations revealed statistically significant results (p < 0.01) for all odorant pairs (Figure S2). Notably, repeating the genotype–phenotype association analysis using the average olfactory threshold score as an additional covariate did not weaken the statistical significance of our results (see Figure 2
Discussion The results presented here provide a link between genetic polymorphism in OR genes and phenotypic variation in human olfaction. Such genetic underpinning for the highly prevalent odorant-specific olfactory threshold differences in the human population has been previously suggested [9,28], but despite multiple reports of a genetic basis for these human phenotypes [11,13,16], the underlying genes remained unknown. Such a genotype–phenotype relationship has been found in the nematode C. elegans, in which an OR gene (odr-10) was shown to be necessary for specific responses to the odorant diacetyl [20]. This result implies that OR gene knockouts may underlie odor-specific threshold differences. Human olfactory SPGs in fact constitute natural knockout alleles, and the findings of the present study imply that they might underlie some of the phenotypic variation in human olfaction. The genetic association between OR11H7P and IVA detection is further supported by in vitro functional analyses of this receptor that suggest a specific response of the intact protein to the odorant. The observation that OR11H4 and OR11H6 also respond to IVA is consistent with the notion that OR proteins from the same subfamily tend to bind similar odorants [29], and suggests that these three closely related OR genes likely confer IVA perception in humans. In view of that, specific hyperosmia for the sweaty odor of IVA would likely occur only in people who carry the intact allele of OR11H7P and hence possess enhanced detection capacity. Nevertheless, we cannot exclude the possibility that the observed association signal in this locus is a result of linkage disequilibrium to other genetic variations such as copy number polymorphisms [30], nonsynonymous SNPs in functionally crucial positions [25], or genetic alterations in regulatory sequences [31]. These could modify the expression levels of one or more receptor genes and could consequently underlie sensitivity differences towards the corresponding ligands of the encoded proteins. The IVA concentration (3 mM) that elicits response from the three receptors from OR11H7Pi and its two other closely related ORs is three orders of magnitude higher than the threshold concentration detectable by individuals with hyperosmia to this odorant. Such differences are consistent with various observations in other studies. For example, olfactory thresholds in mice range from 10−9 to 10−13 M odorant concentration in the vapor phase [32,33], while the concentrations of odorants required for the activation of ORs in the isolated olfactory sensory neurons or in the heterologously expressed ORs were 10−5–10−6 M in the aqueous phase [34,35]. These discrepancies in sensitivity between in vivo responses to odorants in the vapor phase and the responses of dissociated olfactory sensory neurons to odorants in the aqueous phase have been attributed to the presence of olfactory mucus and the airflow in the nasal cavity present in in vivo experiments [36] and absent in the in vitro systems. The human OR gene cluster 14@19.5 is in conserved synteny, and within the same “cluster in conservation” [37] as an OR cluster on mouse Chromosome 14. Notably, in mice, specific olfactory threshold variation to IVA was shown to be in genetic linkage to another OR locus (Iva1) on mouse Chromosome 4 [18,38]. The entire OR cluster in this genomic region is deleted in human [37,38]. Thus, it is possible that two different OR gene loci harbor the genetic basis for IVA sensitivity in the two mammals. The results presented here imply a locus related to specific hyperosmia. Similar enhanced specific olfactory sensitivities have been reported only rarely, although support for a genetic basis for general hyperosmia is found in mice deficient for Neu1 [39] and for the Kcna3 genes [40]. A case of specific hyperosmia, for an unknown urinary metabolite of asparagus, was also attributed to genetic polymorphism in humans [15]; however, the underlying genetic locus has not been identified. This study also highlights the potential phenotypic impact of often-neglected genomic loci—namely, pseudogenes. This is because most eukaryotic mRNA molecules that contain premature translation termination codons are either targeted for rapid degradation by a nonsense-mediated decay mechanism [41] or likely produce truncated nonfunctional protein. Thus, genomic loci annotated as pseudogenes are considered as bearing no functional consequence on the phenotype. Here we demonstrate that an OR annotated as a pseudogene in the public databases may still have a functional allele in the human population and consequently result in a discernible phenotype. Genetic polymorphisms in OR genes likely explain only some of the remarkable threshold variation of human individuals towards particular odorants. Other potential contributing factors are intra-individual fluctuation [6] and environmental factors [14,15,42,43]. The observation of significant inter-odorant threshold correlation within individuals hints at the existence of a common mechanism that affects an individual's overall olfactory sensitivity. This is consistent with the observations of Cain and Gent [6], who postulated that such a mechanism may dominate the outcome of odorant-specific threshold measurements. While this effect could be related to differences in environmental exposures, another appealing possibility is the involvement of other genetic polymorphisms associated with variations in overall olfactory perception. The observation that the association signal between OR11H7P and IVA sensitivity did not change when the general olfactory effect was introduced into the statistical model implies that genetic polymorphisms in OR genes may dictate sensitivity towards particular odorants irrespective of other factors affecting overall olfactory sensitivity. Thus, both hyperosmia and hyposmia, the two extremes of human olfactory threshold distribution, could be driven by both receptor-specific mechanisms and additional elements common to all olfactory sensory neurons either in the olfactory transduction pathway or in processes related to olfactory cognition in the central nervous system. Further research endeavors in this direction would help to unravel additional pieces of the molecular basis of this fascinating complex sensory mechanism. Materials and Methods Participant recruitment. This study was approved by the Institutional Review Board (Helsinki Committee) of Meir Hospital in Kfar Saba, Israel. Human participants (unrelated, randomly selected individuals) were recruited in collaboration with the Israeli Blood Bank (Tel Hashomer) within their blood-drawing sessions. Participants included 197 females and 246 males, aged 18–48 y, originating from three major Jewish ethnicities: 329 Ashkenazi, 61 Sephardic, and 53 Ashkenazi–Sephardic admixtures. Every participant signed an informed consent form and filled in a detailed questionnaire in order to exclude neurological impairments, nose injuries, and other conditions with potential effect on human olfactory acuity. Age, gender, ethnic origin, and smoking habits were also recorded. Olfactory threshold measurements. Odorants, dissolved in light white mineral oil (Sigma) at five 10-fold dilutions between 10−2 M and 10−6 M were presented in Sniffin' Sticks kits [44]. These were replaced every 3 mo to reduce contamination and odorant evaporation. The odorants used were IAA (98%, Aldrich), IVA (99%, Sigma-Aldrich), LCA (97%, Aldrich), and CIN (≥98.5%, Fluka). Detection thresholds were determined using an ascending staircase three-way forced choice procedure [10]. Odor presentation by cap removal was for ~3 s and presentation was ~2 cm in front of both nostrils. A single failure led to the next higher concentration, and detection threshold was the concentration showing four successive correct identifications, assuring a low false positive rate (~0.01). To attain reduction of false negative detection, the immediate subthreshold concentration was retested and claimed threshold if successful. Inter-trial intervals were >20 s, and participants were not given feedback on their performance during the test. All olfactory tests were conducted in a well-ventilated, temperature-controlled, odorless room. A second olfactory measurement was performed within 1–4 wk after the first one for 82 randomly selected individuals to assess test–retest reproducibility. SNP selection and genotyping. Genomic DNA was extracted from 10 ml of peripheral blood using a DNA Isolation Kit for Mammalian Blood (Roche). The DNA concentrations were measured using the Genius spectrophotometer at 260 nm (Tecan) and subsequently normalized to 2.5 ng/μl. Aliquots of 2 μl were distributed in 384 microtiter plates by the Biomek 2000 laboratory automation workstation (Beckman). We employed a candidate gene/SNP approach aimed at detecting the causative genetic polymorphism of human odor-specific threshold variation. Therefore, the underlying SNPs of 52 nonsense and missense SPGs [24,25], SNPs with obvious potential causative effect, were considered for the genotyping effort of this study. SNP genotypes were assessed by the matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) mass spectrometry technology of Sequenom [45]. This procedure involved multiplexes of 10–24 SNP reactions, automatically designed by the SpectroDESIGNER algorithm (Sequenom) and validated for specific genomic amplification using UCSC In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr). SNP genotyping was performed twice, and inconsistencies were removed from further analyses. Overall, high genotyping efficiency (98% ± 3%) was achieved for the 52 polymorphic loci. SNP allele frequencies were tested for deviations from Hardy–Weinberg equilibrium. This test may indicate SNPs with errors in their genotyping process. Consequently, five SNPs were removed from further analysis (Table S2). Four additional SNPs with low minor allele frequency (<0.05; Table S2) were also not included in our association analyses because of the lack of statistical power to detect association even if existed. Thus, a total of 43 polymorphic loci remained for the genotype–phenotype association analysis. OR functional expression. In vitro functional expressions of ORs were carried out as previously described [27]. OR coding regions were amplified from human genomic DNA by PCR using specific primers (BD Biosciences/Clontech), subcloned into a pCI vector (Promega) containing the 20-amino-acid N-terminal sequence of human rhodopsin (to aid in functional expression in this system), and confirmed by sequencing. The disrupting stop codon (TAG) (nucleotide thymine at position 679) of OR11H7P was corrected to a CAG codon for glutamine (as in the intact allele) using the QuickChange II site-directed mutagenesis kit (Stratagene), and verified by sequencing. Each Xenopus laevis oocyte was injected with 25 ng of the receptor cRNA, together with 10 ng of human GNAL cRNA and 1 ng of human CFTR cRNA. Currents, in response to IVA application, were measured under two-electrode voltage clamp. Results are reported as the ratio of current amplitudes elicited by the odorant and the phosphodiesterase inhibitor IBMX. Statistical analysis of functional data was done using one-way ANOVA, followed by Dunnett's post-test. X. laevis frogs were purchased from Nasco. The care and use of X. laevis frogs was approved by the University of Miami Animal Research Committee. Detailed methods for the preparation of oocytes have been previously described [27]. Statistical analyses. Analysis of variance (ANOVA) was used to test the potential effect of gender, ethnic origin (Ashkenazi Jewish, Sephardic Jewish, Ashkenazi–Sephardic Jewish admixture, or other), and smoking habits (>20 cigarettes/day, 11–20 cigarettes/day, 1–10 cigarettes/day, or nonsmoking) on odorant thresholds. Pearson correlation was used to assess the relationship between olfactory threshold and age of the participants. We used ANOVA to test for genotype–phenotype associations by comparing the average olfactory threshold of individuals with different SPG genotypes. For that, we assumed a recessive mode of inheritance (i.e., combining the heterozygous and homozygous intact genotypes) and adding “gender” and “gender by genotype” as other covariates. The recessive hypothesis was explicitly confirmed (F = 1.43, p = 0.24) by calculating the reduced fit between a 2-df test (additive) and 1-df test (recessive) using a likelihood ratio test. The interaction term “gender by genotype” did not have a significant effect (F = 0.17, p = 0.68 for “OR11H7P × gender”), therefore justifying the pooling of sexes in the analyses. The statistical analyses were carried out using the statistical toolbox of Matlab. Figure S1: Test–Retest Reproducibility The first and second thresholds (in –log10 molar concentrations) of 82 individuals are plotted for the four odorants. Circle areas are proportional to the number of participants with similar scores. Test–retest reproducibility is demonstrated by the high correlation coefficient scores. (23 KB PDF) Click here for additional data file.(24K, pdf) Figure S2: Inter-Odorant Threshold Correlations The adjusted thresholds (due to the gender effect) of individuals are plotted for all possible odorant pairs. Modest correlation coefficients (0.12 ≤ R ≤ 0.5, p < 0.01) in the different panels imply that a common denominator has a moderate effect on olfactory sensitivity towards all odorants. (43 KB PDF) Click here for additional data file.(44K, pdf) Table S1: Olfactory Threshold Confounding Factors ANOVA (F) statistics and their corresponding p-values are given for the effect of gender, smoking, and ethnic origin on olfactory threshold variation for the different odorants. Pearson correlation coefficients (R) and their p-values indicate the effect of age on odorant thresholds. (35 KB DOC) Click here for additional data file.(35K, doc) Table S2: OR SPG Information OR SPGs are ordered according to their genomic location. The four genes with minor allele frequency below 0.05 (marked with a number sign) and the five genes with genotypes deviating significantly from Hardy–Weinberg (p < 0.05, Chi-square test; marked with an asterisk) were not included in the genotype–phenotype analyses. (128 KB DOC) Click here for additional data file.(129K, doc) Acknowledgments We thank Dr. B. Yakir for advice in statistical analyses. Abbreviations
Footnotes ¤ Current address: Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America Author contributions. IM, TA, CWL, and DL conceived and designed the experiments. IM and TA performed the experiments. IM, TA, CWL, and DL analyzed the data. SG, VY, and CWL contributed reagent/materials and analysis tools. IM wrote the paper with contributions from TA, YH, CWL, and DL. Funding. This work was supported by National Institute of Health grants DC000298 (DL) and MH66038 (CWL) and by the Crown Human Genome Center. IM is supported by an Eshkol fellowship from the Israeli Ministry of Science, Culture and Sports. DL holds the Ralph and Lois Silver Chair in Human Genomics. Competing interests. The authors have declared that no competing interests exist. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
||||||||||||||||||||||||||||||||||||||||
Arch Otolaryngol Head Neck Surg. 1999 Sep; 125(9):1005-10.
[Arch Otolaryngol Head Neck Surg. 1999]J Exp Psychol Hum Percept Perform. 1991 May; 17(2):382-91.
[J Exp Psychol Hum Percept Perform. 1991]Ann Otol Rhinol Laryngol. 1992 Mar; 101(3):229-36.
[Ann Otol Rhinol Laryngol. 1992]Hum Biol. 1968 Dec; 40(4):456-72.
[Hum Biol. 1968]Ann N Y Acad Sci. 1989; 561():12-28.
[Ann N Y Acad Sci. 1989]Proc Natl Acad Sci U S A. 1984 Aug; 81(15):4899-902.
[Proc Natl Acad Sci U S A. 1984]Neurosci Lett. 1992 Jul 6; 141(1):115-8.
[Neurosci Lett. 1992]Nature. 1973 Mar 23; 242(5395):271-3.
[Nature. 1973]Behav Genet. 1977 Mar; 7(2):171-88.
[Behav Genet. 1977]Cell. 1995 Nov 3; 83(3):407-14.
[Cell. 1995]Cell. 1991 Apr 5; 65(1):175-87.
[Cell. 1991]Genome Res. 2001 May; 11(5):685-702.
[Genome Res. 2001]Genome Biol. 2001; 2(6):RESEARCH0018.
[Genome Biol. 2001]Nat Genet. 2003 Jun; 34(2):143-4.
[Nat Genet. 2003]BMC Bioinformatics. 2006 Aug 29; 7():393.
[BMC Bioinformatics. 2006]J Neurochem. 2006 Jun; 97(5):1506-18.
[J Neurochem. 2006]Nature. 1973 Mar 23; 242(5395):271-3.
[Nature. 1973]Proc Natl Acad Sci U S A. 1984 Aug; 81(15):4899-902.
[Proc Natl Acad Sci U S A. 1984]Cell. 1995 Nov 3; 83(3):407-14.
[Cell. 1995]Dokl Biol Sci. 2002 Nov-Dec; 387():505-7.
[Dokl Biol Sci. 2002]Nature. 2005 Oct 27; 437(7063):1299-320.
[Nature. 2005]Science. 2003 Dec 19; 302(5653):2088-94.
[Science. 2003]Cell. 2006 Jul 28; 126(2):403-13.
[Cell. 2006]Nature. 1967 Jun 10; 214(5093):1095-8.
[Nature. 1967]Ciba Found Symp. 1993; 179():131-41; discussion 141-6.
[Ciba Found Symp. 1993]Nature. 1973 Mar 23; 242(5395):271-3.
[Nature. 1973]Proc Natl Acad Sci U S A. 1984 Aug; 81(15):4899-902.
[Proc Natl Acad Sci U S A. 1984]Neurosci Lett. 1992 Jul 6; 141(1):115-8.
[Neurosci Lett. 1992]Cell. 1999 Mar 5; 96(5):713-23.
[Cell. 1999]Hum Mol Genet. 1998 Jan; 7(1):13-26.
[Hum Mol Genet. 1998]BMC Bioinformatics. 2006 Aug 29; 7():393.
[BMC Bioinformatics. 2006]Nat Rev Genet. 2001 Feb; 2(2):100-9.
[Nat Rev Genet. 2001]Behav Brain Res. 2006 Feb 28; 167(2):349-54.
[Behav Brain Res. 2006]Chem Senses. 2006 Sep; 31(7):655-64.
[Chem Senses. 2006]Cell. 1998 Dec 23; 95(7):917-26.
[Cell. 1998]Cell. 1999 Jan 8; 96(1):1-4.
[Cell. 1999]Neuron. 2006 Dec 7; 52(5):857-69.
[Neuron. 2006]Genome Biol. 2006; 7(10):R88.
[Genome Biol. 2006]Cell. 1995 Nov 3; 83(3):407-14.
[Cell. 1995]Nat Neurosci. 2002 Feb; 5(2):124-33.
[Nat Neurosci. 2002]Proc Natl Acad Sci U S A. 2001 Aug 14; 98(17):9907-12.
[Proc Natl Acad Sci U S A. 2001]Neuron. 2004 Feb 5; 41(3):389-404.
[Neuron. 2004]Br Med J. 1980 Dec 20-27; 281(6256):1676-8.
[Br Med J. 1980]Curr Biol. 2005 Jul 26; 15(14):R559-62.
[Curr Biol. 2005]J Exp Psychol Hum Percept Perform. 1991 May; 17(2):382-91.
[J Exp Psychol Hum Percept Perform. 1991]JAMA. 1990 Dec 5; 264(21):2803.
[JAMA. 1990]Br Med J. 1980 Dec 20-27; 281(6256):1676-8.
[Br Med J. 1980]Occup Med (Lond). 2006 Jan; 56(1):51-4.
[Occup Med (Lond). 2006]Otolaryngol Head Neck Surg. 1979 Nov-Dec; 87(6):717-33.
[Otolaryngol Head Neck Surg. 1979]Chem Senses. 1997 Feb; 22(1):39-52.
[Chem Senses. 1997]Nat Genet. 2003 Jun; 34(2):143-4.
[Nat Genet. 2003]BMC Bioinformatics. 2006 Aug 29; 7():393.
[BMC Bioinformatics. 2006]Hum Mutat. 2001 Apr; 17(4):296-304.
[Hum Mutat. 2001]J Neurochem. 2006 Jun; 97(5):1506-18.
[J Neurochem. 2006]